Pharmacogenomic testing and survival in oesophageal cancer patients, a literature review and results from selected SNPs in the UK MRC OE02 trial
BACKGROUND: Germline single nucleotide polymorphisms (SNPs) are biomarkers that can be readily measured using DNA from peripheral blood or normal tissue. While SNPs have been associated with survival and cytotoxic chemotherapy response in several cancers, limited data exist on the clinical relevance of selected SNPs in oesophageal cancer (OeC) patients. METHODS: DNA was extracted from normal tissue of 480 OeC patients treated with either surgery alone (S, n = 233) or chemotherapy followed by surgery (CS, n = 247) in the OE02 trial. SNPs in DPYD, OPRT, ERCC1, ERCC2 and XRCC1, GSTP1 and TS were analysed using MassARRAY, Sanger sequencing or gel electrophoresis. Associations with clinicopathological variables and overall survival (OS) were investigated. RESULTS: Selected SNP variants were associated with age, tumour differentiation, tumour regression and OS. The OPRT rs1801019 'GC' genotype was more frequent in patients aged >65 years (p = 0.034); the TS 5'UTR '3R/3R' genotype was more frequent in poorly differentiated tumours (p = 0.019) and the ERCC2 rs13181 'GG' genotype was nominally associated with improved tumour regression (p = 0.041). In an exploratory analysis, the ERCC1 rs11615 'CT' genotype was associated with improved OS (HR 0.80, 95%CI: 0.65-0.99, p = 0.040) in the whole cohort and in the subgroup of patients with adenocarcinoma treated by surgery alone. No associations were observed for any of the other SNPs. CONCLUSION: In the largest germline SNP analysis in OeC to date, ERCC1 rs11615 'CT' emerged as a candidate prognostic biomarker warranting validation in an independent cohort.
Authors
- Patrick B. O. Tan (ORCID: https://orcid.org/0000-0002-0179-8048)
- Shahab Jolani (ORCID: https://orcid.org/0000-0002-8508-0702)
- William Allum (ORCID: https://orcid.org/0000-0002-4540-9286)
- Ruth Elizabeth Langley (ORCID: https://orcid.org/0000-0002-9706-016X)
- Shenli Zhang (ORCID: https://orcid.org/0000-0001-9907-9967)
- Heike Irmgard Grabsch (ORCID: https://orcid.org/0000-0001-9520-6228)
- Aaron Shengting Mai (ORCID: https://orcid.org/0000-0002-7644-5538)
- Raghav Sundar (ORCID: https://orcid.org/0000-0001-9423-1368)
- Lindsay C. Hewitt (ORCID: https://orcid.org/0000-0001-5246-2934)
- Matthew Guy Nankivell (ORCID: https://orcid.org/0000-0003-3904-2729)
- Daryl Kai Ann Chia (ORCID: https://orcid.org/0000-0001-9936-1225)
- David Cunningham
- Georgina Anne Keogh
Institutions
- Agency for Science, Technology and Research (SG)
- Ministry of Health (SG)
- University of Leeds (GB)
- Royal Marsden NHS Foundation Trust (GB)
- Institute of Cancer Research (GB)
- SingHealth (SG)
- National University of Singapore (SG)
- Nanyang Technological University (SG)
- Maastricht University Medical Centre (NL)
- Yale University (US)
- Maastricht University (NL)
- MRC Clinical Trials Unit at UCL (GB)
- SingHealth Duke-NUS Academic Medical Centre (SG)
- National University Cancer Institute, Singapore (SG)
- Royal Marsden Hospital (GB)
- Duke-NUS Medical School (SG)
- National Cancer Centre Singapore (SG)
- National University Hospital (SG)
- National Heart Centre Singapore (SG)
- Maastro Clinic (NL)
- Cancer Science Institute of Singapore (SG)
- University College London (GB)
- Genome Institute of Singapore (SG)
Publication Details
- Journal
- Translational Oncology
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1016/j.tranon.2026.103084
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cancer Research UK